Dynacure is a biotechnology company founded in 2016 that is developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare debilitating disease affecting children and young adults. Dynacure’s Dyn101 is an antisense oligonucleotide developed in collaboration with IONIS Pharma (USA).